Safety and Immunogenicity of Recombinant WT1 Antigen-Specific Cancer Immunotherapeutic Combined With Infusion of Treg Depleted T Cells for Adult WT1 Acute Myeloid Leukemia

NCT01513109 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

UNKNOWN

Status

20

Enrollment

OTHER

Sponsor class

Conditions

Acute Myelogenous Leukemia
Myeloid Leukemia in Remission
Effects of Immunotherapy

Interventions

BIOLOGICAL: Recombinant WT1 Antigen-Specific Cancer Immunotherapeutic (ASCI)

Sponsor

Jules Bordet Institute